newsfilter
← Latest News
GlobeNewswire·

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development